423 related articles for article (PubMed ID: 30139767)
1. Non-secreting pituitary tumours characterised by enhanced expression of YAP/TAZ.
Xekouki P; Lodge EJ; Matschke J; Santambrogio A; Apps JR; Sharif A; Jacques TS; Aylwin S; Prevot V; Li R; Flitsch J; Bornstein SR; Theodoropoulou M; Andoniadou CL
Endocr Relat Cancer; 2019 Jan; 26(1):215-225. PubMed ID: 30139767
[TBL] [Abstract][Full Text] [Related]
2. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
Zhu J; Wu T; Lin Q
Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
[TBL] [Abstract][Full Text] [Related]
3. Homeostatic and tumourigenic activity of SOX2+ pituitary stem cells is controlled by the LATS/YAP/TAZ cascade.
Lodge EJ; Santambrogio A; Russell JP; Xekouki P; Jacques TS; Johnson RL; Thavaraj S; Bornstein SR; Andoniadou CL
Elife; 2019 Mar; 8():. PubMed ID: 30912742
[TBL] [Abstract][Full Text] [Related]
4. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
Jang JW; Kim MK; Bae SC
Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
[TBL] [Abstract][Full Text] [Related]
5. TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells.
Finch-Edmondson ML; Strauss RP; Passman AM; Sudol M; Yeoh GC; Callus BA
J Biol Chem; 2015 Nov; 290(46):27928-38. PubMed ID: 26432639
[TBL] [Abstract][Full Text] [Related]
6. An overview of signaling pathways regulating YAP/TAZ activity.
Heng BC; Zhang X; Aubel D; Bai Y; Li X; Wei Y; Fussenegger M; Deng X
Cell Mol Life Sci; 2021 Jan; 78(2):497-512. PubMed ID: 32748155
[TBL] [Abstract][Full Text] [Related]
7. Integrin signalling regulates YAP and TAZ to control skin homeostasis.
Elbediwy A; Vincent-Mistiaen ZI; Spencer-Dene B; Stone RK; Boeing S; Wculek SK; Cordero J; Tan EH; Ridgway R; Brunton VG; Sahai E; Gerhardt H; Behrens A; Malanchi I; Sansom OJ; Thompson BJ
Development; 2016 May; 143(10):1674-87. PubMed ID: 26989177
[TBL] [Abstract][Full Text] [Related]
8. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer.
Jung O; Baek MJ; Wooldrik C; Johnson KR; Fisher KW; Lou J; Ricks TJ; Wen T; Best MD; Cryns VL; Anderson RA; Choi S
EMBO J; 2024 May; 43(9):1740-1769. PubMed ID: 38565949
[TBL] [Abstract][Full Text] [Related]
9. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
10. Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies.
Kim MH; Kim J
Cell Mol Life Sci; 2017 Apr; 74(8):1457-1474. PubMed ID: 27826640
[TBL] [Abstract][Full Text] [Related]
11. Induction of AP-1 by YAP/TAZ contributes to cell proliferation and organ growth.
Koo JH; Plouffe SW; Meng Z; Lee DH; Yang D; Lim DS; Wang CY; Guan KL
Genes Dev; 2020 Jan; 34(1-2):72-86. PubMed ID: 31831627
[TBL] [Abstract][Full Text] [Related]
12. CCM3 is a gatekeeper in focal adhesions regulating mechanotransduction and YAP/TAZ signalling.
Wang S; Englund E; Kjellman P; Li Z; Ahnlide JK; Rodriguez-Cupello C; Saggioro M; Kanzaki R; Pietras K; Lindgren D; Axelson H; Prinz CN; Swaminathan V; Madsen CD
Nat Cell Biol; 2021 Jul; 23(7):758-770. PubMed ID: 34226698
[TBL] [Abstract][Full Text] [Related]
13. YAP/TAZ Initiates Gastric Tumorigenesis via Upregulation of MYC.
Choi W; Kim J; Park J; Lee DH; Hwang D; Kim JH; Ashktorab H; Smoot D; Kim SY; Choi C; Koh GY; Lim DS
Cancer Res; 2018 Jun; 78(12):3306-3320. PubMed ID: 29669762
[TBL] [Abstract][Full Text] [Related]
14. Arterial stiffness induces remodeling phenotypes in pulmonary artery smooth muscle cells via YAP/TAZ-mediated repression of cyclooxygenase-2.
Dieffenbach PB; Haeger CM; Coronata AMF; Choi KM; Varelas X; Tschumperlin DJ; Fredenburgh LE
Am J Physiol Lung Cell Mol Physiol; 2017 Sep; 313(3):L628-L647. PubMed ID: 28642262
[TBL] [Abstract][Full Text] [Related]
15. New insights into the ambivalent role of YAP/TAZ in human cancers.
Luo J; Deng L; Zou H; Guo Y; Tong T; Huang M; Ling G; Li P
J Exp Clin Cancer Res; 2023 May; 42(1):130. PubMed ID: 37211598
[TBL] [Abstract][Full Text] [Related]
16. HERC3 promotes YAP/TAZ stability and tumorigenesis independently of its ubiquitin ligase activity.
Yuan B; Liu J; Shi A; Cao J; Yu Y; Zhu Y; Zhang C; Qiu Y; Luo H; Shi J; Cao X; Xu P; Shen L; Liang T; Zhao B; Feng XH
EMBO J; 2023 Feb; 42(4):e111549. PubMed ID: 36598329
[TBL] [Abstract][Full Text] [Related]
17. YAP/TAZ at the Roots of Cancer.
Zanconato F; Cordenonsi M; Piccolo S
Cancer Cell; 2016 Jun; 29(6):783-803. PubMed ID: 27300434
[TBL] [Abstract][Full Text] [Related]
18. YAP/TAZ for cancer therapy: opportunities and challenges (review).
Guo L; Teng L
Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
[TBL] [Abstract][Full Text] [Related]
19. The Hippo Pathway in Prostate Cancer.
Salem O; Hansen CG
Cells; 2019 Apr; 8(4):. PubMed ID: 31018586
[TBL] [Abstract][Full Text] [Related]
20. Metabolic control of YAP and TAZ by the mevalonate pathway.
Sorrentino G; Ruggeri N; Specchia V; Cordenonsi M; Mano M; Dupont S; Manfrin A; Ingallina E; Sommaggio R; Piazza S; Rosato A; Piccolo S; Del Sal G
Nat Cell Biol; 2014 Apr; 16(4):357-66. PubMed ID: 24658687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]